Related Experiment Videos
Ototoxicity associated with intravenous bisphosphonate administration
I R Reid1, D A Mills, D J Wattie
1Department of Medicine, University of Auckland, New Zealand.
Calcified Tissue International
|June 1, 1995
Summary
Pamidronate treatment for Paget
Area of Science:
- Ototoxicity and Pharmacology
- Bone Metabolism and Therapeutics
Background:
- Paget's disease of bone is a chronic condition affecting bone remodeling.
- Intravenous bisphosphonates, such as pamidronate, are used to manage Paget's disease.
Observation:
- A patient undergoing intravenous pamidronate treatment for Paget's disease experienced ototoxicity.
- Symptoms included hearing loss, vertigo, and tinnitus, worsening with further infusions.
Findings:
- This case report details the onset of ototoxicity linked to pamidronate therapy in Paget's disease.
- The observed ototoxic effects were directly correlated with pamidronate administration.
Implications:
- This highlights a previously unreported potential adverse effect of pamidronate in Paget's disease patients.
- Clinicians should monitor for auditory and vestibular symptoms during pamidronate treatment.
- Further research is warranted to understand the mechanism and incidence of pamidronate-induced ototoxicity.